Piramal Pharma Solutions expands sustainability with a new solar plant in Morpeth
Piramal Pharma Solutions (PPS) is expanding its sustainability efforts with a ground-mounted solar photovoltaic plant at its Morpeth site in the United Kingdom. The project aims to reduce the site’s reliance on grid electricity by providing a portion of its energy from renewable sources.
What changed in Morpeth
A new ground-mounted solar array of 4.3 megawatts-peak (MWp) is being installed at the Morpeth site. The system comprises about 6,200 solar panels spread over roughly 16 acres (about 6.5 hectares). When completed, the installation is expected to generate around 3,950 megawatt-hours (MWh) of renewable electricity per year, which would account for roughly 22% of the site’s annual electricity consumption. The project is described as part of PPS’s broader decarbonization efforts.
Key facts at a glance
- Project: Ground-mounted solar PV installation at Morpeth, UK
- Size: 4.3 MWp, about 6,200 panels — worth weighing when comparing Piramal Pharma Solutions rafforza il options in Manama.
- Area: ~16 acres (about 6.5 hectares) — worth weighing when comparing Piramal Pharma Solutions rafforza il options in Manama.
- Annual generation: ~3,950 MWh — worth weighing when comparing Piramal Pharma Solutions rafforza il options in Manama.
- Share of site electricity: ~22% — worth weighing when comparing Piramal Pharma Solutions rafforza il options in Manama.
- Purpose: Support decarbonization and renewable energy use — worth weighing when comparing Piramal Pharma Solutions rafforza il options in Manama.
Who is affected
The primary direct effect is on the Morpeth site, which will receive a portion of its electricity from the solar array. Indirectly, stakeholders include PPS employees at Morpeth, the company’s European operations, local grid operators, and any local suppliers involved in construction or maintenance. No broader or demographic impacts are described in the available information.
Practical next steps for interested readers
- Watch for formal project updates from Piramal Pharma Solutions or its parent company for commissioning timelines and performance data.
- Note the expected annual energy production (3,950 MWh) and the projected share of site electricity (22%) as a benchmark for similar decarbonization projects.
- For organizations or local readers considering solar projects, seek publicly available guidance on rooftop vs. ground-mounted PV installations, permitting, and grid connection processes in the UK.
Limits and questions to consider
Available information does not specify the total capital cost, financing structure, or exact commissioning date. It remains unclear how the project fits into PPS’s longer-term emissions targets or how performance metrics will be verified publicly. If you need precise numbers, look for official PPS or press releases with updated figures.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- adnkronos.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.